摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[(1Z)-buta-1,3-dienyl]-2-methyl-1H-pyrrole

中文名称
——
中文别名
——
英文名称
3-[(1Z)-buta-1,3-dienyl]-2-methyl-1H-pyrrole
英文别名
——
3-[(1Z)-buta-1,3-dienyl]-2-methyl-1H-pyrrole化学式
CAS
——
化学式
C9H11N
mdl
——
分子量
133.19
InChiKey
MURYAKQBFQSHCJ-PLNGDYQASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    15.8
  • 氢给体数:
    1
  • 氢受体数:
    0

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
    申请人:MEDIVATION TECHNOLOGIES INC
    公开号:WO2015058084A1
    公开(公告)日:2015-04-23
    The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of ΡΒΚδ, and compounds that are dual inhibitors of both Btk and PI3Kδ. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3Kδ provides a therapeutic benefit to a patient having the disease.
    本申请公开了抑制Btk的化合物、抑制ΡΒΚδ的化合物,以及既是Btk又是PI3Kδ的双重抑制剂的化合物。还描述了合成这些抑制剂的方法,以及利用这些抑制剂治疗疾病的方法,其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。
  • ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS
    申请人:ASTEX THERAPEUTICS LIMITED
    公开号:US20140303177A1
    公开(公告)日:2014-10-09
    The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q 1 is a bond or a saturated C 1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONR q or NR q CO where R q is hydrogen or methyl, or R q is a C 1-4 alkylene chain linked to R or a carbon atom of Q 1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q 1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q 2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Q 2 is other than a bond; G is hydrogen, NR 2 R 3 , OH or SH provided that when E is aryl or heteroaryl and Q 2 is a bond, then G is hydrogen; R 1 is hydrogen or an aryl or heteroaryl group, with the proviso that when R is hydrogen and G is NR 2 R 3 , then Q is a bond; and R 2 , R 3 , R 4 , R 6 and R 8 are as defined in the claims.
    本发明提供了一种用作蛋白激酶B抑制剂的化合物,该化合物是公式(I)的化合物或其盐、溶剂化合物、互变异构体或N-氧化物,其中T为N或CR5;J1-J2为N═C(R6)、(R7)C═N、(R8)N—C(O)、(R8)2C—C(O)、N═N或(R7)C═C(R6);E为5或6个环元素的单环碳环或杂环基团,其中杂环基团最多包含3个从O、N和S中选择的杂原子;Q1为键或饱和的C1-3烃基连接基团,连接基团中的一个碳原子可以被氧或氮原子替换,或者相邻的一对碳原子可以被CONRq或NRqCO替换,其中Rq为氢或甲基,或者Rq为C1-4烷基链,连接到R或Q1的碳原子以形成环状基团;连接基团Q1的碳原子可以选择地带有一个或多个和羟基取代基;Q2为键或含有1至3个碳原子的饱和烃基连接基团,其中连接基团中的一个碳原子可以选择地被氧或氮原子替换;连接基团的碳原子可以选择地带有一个或多个和羟基取代基,但当存在羟基时,其不位于与G基团相关的碳原子a上;并且当E为芳基或杂芳基时,Q2不是键;G为氢、NR2R3、OH或SH,但当E为芳基或杂芳基且Q2为键时,G为氢;R1为氢或芳基或杂芳基,但当R为氢且G为NR2R3时,Q为键;而R2、R3、R4、R6和R8如权利要求所定义。
  • Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors
    申请人:ASTEX THERAPEUTICS LIMITED
    公开号:US20140107137A1
    公开(公告)日:2014-04-17
    The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q 1 is a bond or a saturated C 1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONR q or NR q CO where R q is hydrogen or methyl, or R q is a C 1-4 alkylene chain linked to R 1 or a carbon atom of Q 1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q 1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q 2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Q 2 is other than a bond; G is hydrogen, NR 2 R 3 , OH or SH provided that when E is aryl or heteroaryl and Q 2 is a bond, then G is hydrogen; R 1 is hydrogen or an aryl or heteroaryl group, with the proviso that when R 1 is hydrogen and G is NR 2 R 3 , then Q 2 is a bond; and R 2 , R 3 , R 4 , R 6 and R 8 are as defined in the claims.
    本发明提供了一种用作蛋白激酶B抑制剂的化合物,该化合物是公式(I)的化合物或其盐,溶剂化合物,互变异构体或N-氧化物,其中T为N或CR5; J1-J2为N═C(R6),(R7)C═N,(R8)N—C(O),(R8)2C—C(O),N═N或(R7)C═C(R6);E为5个或6个环元素的单环碳环或杂环基团,所述杂环基团中包含最多3个从O、N和S中选择的杂原子;Q1为键或饱和的C1-3烃基连接基团,其中连接基团中的一个碳原子可以选择性地被氧或氮原子所取代,或者相邻的一对碳原子可以被CONRq或NRqCO所取代,其中Rq为氢或甲基,或Rq为C1-4烷基链,与R1或Q1的一个碳原子连接,形成一个环状基团;连接基团Q1的碳原子可以选择性地带有一个或多个和羟基取代基;Q2为键或含有1至3个碳原子的饱和烃基连接基团,其中连接基团中的一个碳原子可以选择性地被氧或氮原子所取代;连接基团的碳原子可以选择性地带有一个或多个和羟基取代基,但是当存在羟基基团时,不得位于G基团相对的碳原子上;并且当E为芳基或杂芳基时,则Q2不是键;G为氢,NR2R3,OH或SH,但是当E为芳基或杂芳基且Q2为键时,G为氢;R1为氢或芳基或杂芳基,但是当R1为氢且G为NR2R3时,Q2为键;R2、R3、R4、R6和R8如权利要求所定义。
  • Package structure and method of manufacturing the same
    申请人:Taiwan Semiconductor Manufacturing Co., Ltd.
    公开号:US11164839B2
    公开(公告)日:2021-11-02
    A package structure includes a semiconductor die and a redistribution circuit structure. The redistribution circuit structure is disposed on and electrically connected to the semiconductor die and includes a patterned conductive layer, a dielectric layer, and an inter-layer film. The dielectric layer is disposed on the patterned conductive layer. The inter-layer film is sandwiched between the dielectric layer and the patterned conductive layer, and the patterned conductive layer is separated from the dielectric layer through the inter-layer film.
    一种封装结构包括一个半导体裸片和一个再分布电路结构。再分布电路结构设置在半导体裸片上并与半导体裸片电连接,包括图案化导电层、介质层和层间薄膜。电介质层设置在图案化导电层上。层间薄膜夹在电介质层和图案化导电层之间,图案化导电层通过层间薄膜与电介质层隔开。
  • METALLIC SURFACE ENHANCEMENT
    申请人:MacDermid Enthone Inc.
    公开号:EP2142485B1
    公开(公告)日:2019-07-24
查看更多